Lynda Charters

The epidemiology, inflammatory pathophysiology, diagnosis, and treatment of diabetic macular edema are discussed during Inflammatory Eye Disease Week.

Spectacle lenses with highly aspherical lenslets are safe and effective for reducing myopia progression in US children.

A higher risk of central serous chorioretinopathy and serous pigment epithelial detachment are associated with varicose veins.

Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for optometrists managing near vision loss.

Enspryng is the first subcutaneous, at-home treatment option for TED and the first interleukin (IL)-6 receptor inhibitor approved in the indication.

Noab Banoub, a third year medical student, describes his journey into medicine and his view of ophthalmology's future.

Uveitis is uncommon, but it causes a disproportionate share of visual morbidity.

Anti-VEGF for ROP is not associated with systemic and neurodevelopmental outcomes.

The evidence for nutrition in eye care is strong for some conditions and thin or absent for others.

A cataract expert discussed if postoperative topical antibiotics add protection after intracameral prophylaxis.

A glaucoma expert addressed the connection between systemic blood pressure, intraocular pressure, and glaucoma.

Stuart Therapeutics Inc. submitted an investigational NDA amendment to the FDA to study ST-100 (vezocolmitide) in corneal wound healing.

As with so many diseases, lung cancer manifests in men and women differently in type, symptoms, and prognosis.

• The American Academy of Ophthalmology 2026 annual meeting is set for October 9-12 in New Orleans.

Women’s systemic and ocular health associated with pregnancy is a focus at EURETINA 2026 in Vienna.

Inherited metabolic diseases affect the retina even before the systemic diagnosis is established.

Aldeyra Therapeutics will submit a FDRR to the FDA for reproxalap, an investigational drug or dry eye disease.

Non-invasive electrical stimulation delivered through closed eyelids improved retinal structure and photoreceptor function.

Patient enrollment is complete in the the ASTRA phase 3 study AURN001 to treat corneal edema associated with corneal endothelial dysfunction.

Subretinal deposits are linked to worse surgical risks in patients with severe aortic stenosis and reduced systemic blood flow.

One subretinal injection of medium-dose OCU410 gene therapy reduced geographic atrophy growth by up to 32%.

EyeCon is an opportunity for ophthalmologists and optometrists to sit down together.

The first patients were dosed in the global phase 3 ORBIT trial evaluating linsitinib as an oral therapy for thyroid eye disease.

Q3 2026 delivered advances in some closely watched pipeline products.

Atrial fibrillation appears to cause thinning of the macular ganglion cell and inner plexiform layer.

In patients reporting chronic ocular pain, dry eye may not be the entire diagnosis.

Polish investigators showed that various modalities can quantify ocular changes in attention deficit/hyperactivity disorder.

Opus Genetics announced positive 3- and 6-month results OPGx-BEST1 in BEST1-related retinal diseases.

Startup S5G Therapeutics aims to move ubiquinol technology from the laboratory toward treatments for dry eye, Fuchs dystrophy, and other corneal conditions.

Women are more often affected than men, and the disease manifests differently between the sexes.